Nath Bio-Genes (India) Share Price
153.10+0.03 (+0.02%)
-9.52% past 1 Year
Nath Bio-Genes is amongst the pioneering seed companies in India. The company has a strong Research & Development arm. It has research laboratories irrigated land testing facilities and farms all
Corporate filings & documents
Announcements
Record Date for the AGM and Dividend
2 days agoRecord Date for the AGM and Dividend
2 days agoNotice of Annual General Meeting and Annual Report
2 days agoNotice of Annual General Meeting and Annual Report
2 days agoNotice of Annual General Meeting and Annual Report 2025-26
2 days agoNotice of Annual General Meeting and Annual Report 2025-26
2 days agoIntimation of Initiation of Forensic Audit
4 weeks agoIntimation of Initiation of Forensic Audit
4 weeks agoInvestor Presentation on Unaudited Financial Results as of 30th June 2026
1 month agoInvestor Presentation on Unaudited Financial Results as of 30th June 2026
1 month agoOutcome of Board Meeting: Unaudited Financial results as of 30th June 2026.
1 month agoOutcome of Board Meeting: Unaudited Financial results as of 30th June 2026.
1 month agoCompliance Certificate under Reg 74 (5) of SEBI (DP) Regulations
1 month agoCompliance Certificate under Reg 74 (5) of SEBI (DP) Regulations
1 month agoNath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 inter alia to consider and approve Unaudited financial results as of 30th June 2026
1 month agoNath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 inter alia to consider and approve Unaudited financial results as of 30th June 2026
1 month agoClosure of Trading Window
2 months agoClosure of Trading Window
2 months agoAnnual Secretarial Compliance Report for 31st March 2026.
3 months agoEarning Call Transcript held on 05th May 2026
3 months agoEarning Call Transcript held on 05th May 2026
3 months agoAudio Transcript of Concall held on 05th May 2026.
3 months agoAudio Transcript of Concall held on 05th May 2026.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Nath Bio-Genes (India) Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L01110MH1993PLC072842</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>BBB+</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>INDIA RATINGS AND RESEARCH PVT. LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Dhiraj Rathi <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Amol Gupta <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 11/05/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Nath Bio-Genes (India) Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L01110MH1993PLC072842</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>BBB+</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>INDIA RATINGS AND RESEARCH PVT. LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Dhiraj Rathi <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Amol Gupta <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 11/05/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
3 months agoInvestor Presentation on Financial Results as on 31st March 2026
4 months agoInvestor Presentation on Financial Results as on 31st March 2026
4 months agoOutcome of Board Meeting held on 04th May 2026
4 months agoOutcome of Board Meeting held on 04th May 2026
4 months agoAudited Financial Results as on 31st March 2026.
4 months agoAudited Financial Results as on 31st March 2026.
4 months agoIntimation for Earning Conference Call to be held on Tuesday 05th May 2026 at 04:00 PM.
4 months agoNath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 inter alia to consider and approve Financial Results as on 31st March 2026.
4 months agoNath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 inter alia to consider and approve Financial Results as on 31st March 2026.
4 months agoCompliance Certificate under SEBI (DP) Regulation.
4 months agoCompliance Certificate under SEBI (DP) Regulation.
4 months agoClosure of Trading Window
5 months agoClosure of Trading Window
5 months agoInvestor Presentation of Financial Results as on 31st December 2025
7 months agoIssue of Duplicate Share Certificate
7 months agoFinancial Results as on 31st December 2025.
7 months agoNath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2026 inter alia to consider and approve Financial Results as on 31st December 2025
7 months agoCompliance Certificate under Reg 74
7 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Tapovan Paper and Board Mills Ltd & Others
7 months agoClosure of Trading window
8 months agoEarning Call Transcript
9 months agoInvestor Presentation on financial results as on 30th September 2025.
9 months agoOutcome of Board Meeting
9 months agoUnaudited Financial Results as on 30th September 2025
9 months agoThe Earning conference call of the Company is scheduled to be held on Friday 14th November 2025 at 12:30 PM IST.
9 months agoAnnual reports
Concalls & investor presentations
Jul 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Jul 2025
ConcallPresentation
Apr 2025
ConcallPresentation
Apr 2025
ConcallPresentation
Jan 2025
ConcallPresentation
Oct 2024
ConcallPresentation
Oct 2024
ConcallPresentation
Aug 2024
ConcallPresentation
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Jan 2024
ConcallPresentation
Oct 2023
ConcallPresentation
Oct 2023
ConcallPresentation
Aug 2023
ConcallPresentation
Apr 2023
ConcallPresentation
Apr 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Oct 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
ConcallPresentation
Aug 2021
ConcallPresentation
Jun 2021
ConcallPresentation
Jun 2021
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2025-08-14
Dividend
2.0
2024-08-09
Dividend
2.0
2023-07-04
Dividend
2.0
2022-06-23
Dividend
2.0
2021-08-18
Dividend
2.0
Company details
Registered office
Nath House, Nath Road P B No 318 NULL Chhatrapati Sambhajinagar - (Aurangabad) Maharashtra PIN: 431005 Tel No: 0240-2376314-7 Fax No: 0240-2376188 Email: [email protected] / [email protected] Internet: www.nathbiogenes.com
Registrars
Office No S6-2, 6th Floor, Pinnacle Business Park,ext to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093(old address - Bharat Tin Works building, 1st floor, Opp. Vasant Oasis, Andheri East Mumbai - 400 059Tel: + 91 21 626 38200Fax: Office No S6-2, 6th Floor, Pinnacle Business Park Next to Ahura Centre, Mahakali Caves Road Andheri (E) PIN: Tel No: 91-022-62638200 Fax No: 91-022-62638299 Email: [email protected]
Management
Satish Kagliwal, Managing Director
Jeevanlata Kagliwal, Executive Director
Akash Kagliwal, Promoter & Non-Executive Director
Hitesh Purohit, Independent Non-Executive Director
Vadla Nagbhushanam, Independent Non-Executive Director
Madhukar Deshpande, Independent Non-Executive Director
Shipra Agrawal, Independent Non-Executive Director
Dhiraj Rathi, Company Secretary & Compliance Officer
Details
BSE 537291
NSE NATHBIOGEN
ISIN INE448G01010